Pediatric and Adolescent Osteosarcoma pp 309-318

Part of the Cancer Treatment and Research book series (CTAR, volume 152) | Cite as

Treatment of Osteosarcoma. The Scandinavian Sarcoma Group Experience

  • Øyvind S. Bruland
  • Henrik Bauer
  • Thor Alvegaard
  • Sigbjørn Smeland
Chapter

Abstract

Results from four consecutive trials, conducted from 1982 by members of the Scandinavian Sarcoma Group, are reviewed. A total of 330 classical osteosarcoma patients were enrolled. In all trials chemotherapy was based on the three active drugs, methotrexate, doxorubicin and cisplatinum and for the latter trials also ifosfamide. Post-operative chemotherapy was stratified by histological response to up-front treatment.

References

  1. 1.
    Malawer MM, Helman LJ, O’Sullivan B. Sarcomas of bone. In: Devita VT, Hellman S, Rosenberg SA, eds. Cancer – Principles & Practice of Oncology. 7th ed. Philadelphia: Lippincott-Raven Publishers; 2005:1638-1686.Google Scholar
  2. 2.
    Souhami R, Cannon SR. Osteosarcoma. In: Peckham M, Pinedo HM, Veronesi U, eds. Oxford Textbook of Oncology. Oxford: Oxford University Press; 1995:1969-1976.Google Scholar
  3. 3.
    Huvos AG. Osteogenic sarcoma. In: Huvos AG, ed. Bone Tumors. Diagnosis, Treatment and Prognosis. Philadelphia: WB Saunders; 1991:85-155.Google Scholar
  4. 4.
    Dahlin D, Unni K. Osteogenic sarcoma of bone and its important recognizable varieties. Am J Surg Pathol. 1977;1:61-72.CrossRefPubMedGoogle Scholar
  5. 5.
    Bruland OS, Pihl A. On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy. Eur J Cancer. 1997;33(11):1725-1731.CrossRefPubMedGoogle Scholar
  6. 6.
    Cade S. Osteogenic sarcoma: a study based on 133 patients. J R Coll Surg Edinb. 1955;1:79-111.PubMedGoogle Scholar
  7. 7.
    Rosen G, Marcove RC, Caparros B. Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer. 1979;43:2163-2177.CrossRefPubMedGoogle Scholar
  8. 8.
    Del Prever AB, Smeland S, Tienghi A, et al. High-risk osteosarcoma (OS): preliminary results of the ISG-SSG II protocol. ASCO Meet Abstr. 2005;23(26):9002.Google Scholar
  9. 9.
    Saeter G, Alvegard TA, Elomaa I, Stenwig AE, et al. Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study. J Clin Oncol. 1991;9:1766-1775.PubMedGoogle Scholar
  10. 10.
    Smeland S, Muller C, Alvegard TA, et al. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer. 2003;39:488-494.CrossRefPubMedGoogle Scholar
  11. 11.
    Ferrari S, Smeland S, Mercury M, et al. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol. 2005;23:8845-8852.CrossRefPubMedGoogle Scholar
  12. 12.
    Alvegård TA, Rydholm A, eds. The Scandinavian Sarcoma Group. 25 years’ experience. Acta Orthop Scand. 2004;75(Suppl 311):1-114.Google Scholar
  13. 13.
    Saeter G, Bruland OS, Follerås G, et al. Extremity and non-extremity high-grade osteosarcoma – the Norwegian Radium Hospital experience during the modern chemotherapy era. Acta Oncol. 1996;35(Suppl 8):129-134.CrossRefPubMedGoogle Scholar
  14. 14.
    Sæter G and Bruland, ØS. High-grade osteosarcoma: The scope beyond the classical patient. 21-23 In: Towards the Eradication of Osteosarcoma Metastases – An Odyssey; 1998. ISBN 82-91929-02-5Google Scholar
  15. 15.
    Bruland ØS, Kleppe H, Sæter G, et al. Hematogenous micrometases in osteosarcoma patients. Clin Cancer Res. 2005;11(13):4666-4673.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Øyvind S. Bruland
    • 1
  • Henrik Bauer
  • Thor Alvegaard
  • Sigbjørn Smeland
  1. 1.The Norwegian Radium HospitalUniversity of OsloOsloNorway

Personalised recommendations